메뉴 건너뛰기




Volumn 28, Issue 3, 2013, Pages 187-195

In vivo and in vitro studies on renal uptake of radiolabeled affibody molecules for imaging of HER2 expression in tumors

Author keywords

Affibody molecules; ER2; Megalin; OK cells; Renal reabsorption

Indexed keywords

CUBILIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MEGALIN; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; Z EPIDERMAL GROWTH FACTOR RECEPTOR 2:2395 CYSTINE IN 11; Z EPIDERMAL GROWTH FACTOR RECEPTOR 2:2395 CYSTINE TC 99M; Z INSULIN:810 TC 99M; Z TAQ POLYMERASE:1154 TC 99M;

EID: 84876105082     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2012.1304     Document Type: Article
Times cited : (31)

References (41)
  • 1
    • 0018974089 scopus 로고
    • The development and use of radiolabeled antitumor antibodies
    • Presman D. The development and use of radiolabeled antitumor antibodies. Cancer Res 1980;40:2960
    • (1980) Cancer Res , vol.40 , pp. 2960
    • Presman, D.1
  • 2
    • 77949895194 scopus 로고    scopus 로고
    • Preclinical and clinical studies of peptide receptor radionuclide therapy
    • Pool SE, Krenning EP, Koning GA, et al. Preclinical and clinical studies of peptide receptor radionuclide therapy. Semin Nucl Med 2010;40:209
    • (2010) Semin Nucl Med , vol.40 , pp. 209
    • Pool, S.E.1    Krenning, E.P.2    Koning, G.A.3
  • 3
    • 69449106959 scopus 로고    scopus 로고
    • Peptide-receptor radionuclide therapy for endocrine tumors
    • van Essen M, Krenning EP, Kam BL, et al. Peptide-receptor radionuclide therapy for endocrine tumors. Nat Rev Endocrinol 2009;5:382
    • (2009) Nat Rev Endocrinol , vol.5 , pp. 382
    • Van Essen, M.1    Krenning, E.P.2    Kam, B.L.3
  • 5
    • 0031911476 scopus 로고    scopus 로고
    • Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: Present status, future prospects and limitations
    • Behr TM, Goldenberg DM, Becker W. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: Present status, future prospects and limitations. Eur J Nucl Med 1998;25:201
    • (1998) Eur J Nucl Med , vol.25 , pp. 201
    • Behr, T.M.1    Goldenberg, D.M.2    Becker, W.3
  • 6
    • 14844358655 scopus 로고    scopus 로고
    • Long-term followup of renal function after peptide receptor radiation therapy with 90Y-DOTA0,Tyr3-Octreotide and 177Lu-DOTA0,Tyr3- Octreotate
    • Valkema R, Pauwels SA, Kvols LK, et al. Long-term followup of renal function after peptide receptor radiation therapy with 90Y-DOTA0,Tyr3-Octreotide and 177Lu-DOTA0,Tyr3- Octreotate. J Nucl Med 2005;46:83S.
    • (2005) J Nucl Med , vol.46
    • Valkema, R.1    Pauwels, S.A.2    Kvols, L.K.3
  • 7
    • 0036843101 scopus 로고    scopus 로고
    • Megalin and cubilin-the story of two multipurpose receptors unfold
    • Verroust PJ, Christensen EI. Megalin and cubilin-the story of two multipurpose receptors unfold. Nephrol Dial Transplant 2002;17:1867
    • (2002) Nephrol Dial Transplant , vol.17 , pp. 1867
    • Verroust, P.J.1    Christensen, E.I.2
  • 8
    • 33644665426 scopus 로고    scopus 로고
    • Megalin Is Essential for Renal Proximal Tubule Reabsorption of 111In-DTPAOctreotide
    • de Jong M, Barone R, Krenning E, et al. Megalin Is Essential for Renal Proximal Tubule Reabsorption of 111In-DTPAOctreotide. J Nucl Med 2005;46:1696
    • (2005) J Nucl Med , vol.46 , pp. 1696
    • De Jong, M.1    Barone, R.2    Krenning, E.3
  • 9
    • 77949273386 scopus 로고    scopus 로고
    • Albumin-derived peptides efficiently reduce renal uptake of radiolabelled peptides
    • Vegt E, Eek A, Oyen WJ, et al. Albumin-derived peptides efficiently reduce renal uptake of radiolabelled peptides. Eur J Nucl Med Mol Imaging 2010;37:226
    • (2010) Eur J Nucl Med Mol Imaging , vol.37 , pp. 226
    • Vegt, E.1    Eek, A.2    Oyen, W.J.3
  • 10
    • 25144519114 scopus 로고    scopus 로고
    • Localisation and mechanism of renal retention of radiolabelled somatostatin analogues
    • Melis M, Krenning EP, Bernard BF, et al. Localisation and mechanism of renal retention of radiolabelled somatostatin analogues. Eur J Nucl Med Mol Imaging 2005;32:1136
    • (2005) Eur J Nucl Med Mol Imaging , vol.32 , pp. 1136
    • Melis, M.1    Krenning, E.P.2    Bernard, B.F.3
  • 11
    • 79953708503 scopus 로고    scopus 로고
    • Renal uptake of different radiolabelled peptides is mediated by megalin: SPECT and biodistribution studies in megalin-deficient mice
    • Vegt E, Melis M, Eek A, et al. Renal uptake of different radiolabelled peptides is mediated by megalin: SPECT and biodistribution studies in megalin-deficient mice. Eur J Nucl Med Mol Imaging 2011;38:623
    • (2011) Eur J Nucl Med Mol Imaging , vol.38 , pp. 623
    • Vegt, E.1    Melis, M.2    Eek, A.3
  • 12
    • 77954966119 scopus 로고    scopus 로고
    • Renal toxicity of radiolabeled peptides and antibody fragments: Mechanisms, impact on radionuclide therapy, and strategies for prevention
    • Vegt E, de Jong M, Wetzels JFM, et al. Renal toxicity of radiolabeled peptides and antibody fragments: Mechanisms, impact on radionuclide therapy, and strategies for prevention. J Nucl Med 2010;51:1049
    • (2010) J Nucl Med , vol.51 , pp. 1049
    • Vegt, E.1    De Jong, M.2    Wetzels, J.F.M.3
  • 13
    • 34248549130 scopus 로고    scopus 로고
    • Indication for different mechanisms of kidney uptake of radiolabeled peptides
    • Gotthardt M, van Eerd-Vismale J, Oyen WJ, et al. Indication for different mechanisms of kidney uptake of radiolabeled peptides. J Nucl Med 2007;48:596
    • (2007) J Nucl Med , vol.48 , pp. 596
    • Gotthardt, M.1    Van Eerd-Vismale, J.2    Oyen, W.J.3
  • 14
    • 43549101411 scopus 로고    scopus 로고
    • Alternative binding proteins: Affibody binding proteins developed from a small three-helix bundle scaffold
    • Nygren PA. Alternative binding proteins: Affibody binding proteins developed from a small three-helix bundle scaffold. FEBS J 2008;275:2668
    • (2008) FEBS J , vol.275 , pp. 2668
    • Nygren, P.A.1
  • 15
    • 77953130101 scopus 로고    scopus 로고
    • Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applications
    • Löfblom J, Feldwisch J, Tolmachev V, et al. Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett 2010;584:2670
    • (2010) FEBS Lett , vol.584 , pp. 2670
    • Löfblom, J.1    Feldwisch, J.2    Tolmachev, V.3
  • 16
    • 79952118497 scopus 로고    scopus 로고
    • Radionuclide molecular imaging using Affibody molecules
    • Ahlgren S, Tolmachev V. Radionuclide molecular imaging using Affibody molecules. Curr Pharm Biotechnol 2010;11:581
    • (2010) Curr Pharm Biotechnol , vol.11 , pp. 581
    • Ahlgren, S.1    Tolmachev, V.2
  • 17
    • 77953927395 scopus 로고    scopus 로고
    • Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules
    • Baum RP, Prasad V, Müller D, et al. Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules. J Nucl Med 2010;51:892
    • (2010) J Nucl Med , vol.51 , pp. 892
    • Baum, R.P.1    Prasad, V.2    Müller, D.3
  • 18
    • 33947672248 scopus 로고    scopus 로고
    • Radionuclide therapy of HER2-positive microxenografts using a 177Lulabeled HER2-specific Affibody molecule
    • Tolmachev V, Orlova A, Pehrson R, et al. Radionuclide therapy of HER2-positive microxenografts using a 177Lulabeled HER2-specific Affibody molecule. Cancer Res 2007; 67:2773
    • (2007) Cancer Res , vol.67 , pp. 2773
    • Tolmachev, V.1    Orlova, A.2    Pehrson, R.3
  • 19
    • 58149305658 scopus 로고    scopus 로고
    • Development and preclinical characterisation of 99mTc-labelled Affibody molecules with reduced renal uptake
    • Ekblad T, Tran T, Orlova A, et al. Development and preclinical characterisation of 99mTc-labelled Affibody molecules with reduced renal uptake. Eur J Nucl Med Mol Imaging 2008;35:2245
    • (2008) Eur J Nucl Med Mol Imaging , vol.35 , pp. 2245
    • Ekblad, T.1    Tran, T.2    Orlova, A.3
  • 20
    • 77949268342 scopus 로고    scopus 로고
    • Re-maSGS-Z (HER2:342), a potential Affibody conjugate for systemic therapy of HER2-expressing tumours
    • Orlova A, Tran TA, Ekblad T, et al. (186)Re-maSGS-Z (HER2:342), a potential Affibody conjugate for systemic therapy of HER2-expressing tumours. Eur J Nucl Med Mol Imaging 2010;37:260
    • (2010) Eur J Nucl Med Mol Imaging , vol.37 , pp. 260
    • Orlova, A.1    Tran, T.A.2    Ekblad, T.3
  • 21
    • 79952798198 scopus 로고    scopus 로고
    • Molecular design and optimization of 99mTc-labeled recombinant affibody molecules improves their biodistribution and imaging properties
    • Wallberg H, Orlova A, Altai M, et al. Molecular design and optimization of 99mTc-labeled recombinant affibody molecules improves their biodistribution and imaging properties. J Nucl Med 2011;52:461
    • (2011) J Nucl Med , vol.52 , pp. 461
    • Wallberg, H.1    Orlova, A.2    Altai, M.3
  • 22
    • 38949103710 scopus 로고    scopus 로고
    • Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant affibody molecules
    • Ahlgren S, Orlova A, Rosik D, et al. Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant affibody molecules. Bioconjug Chem 2008;19:235
    • (2008) Bioconjug Chem , vol.19 , pp. 235
    • Ahlgren, S.1    Orlova, A.2    Rosik, D.3
  • 23
    • 66149150263 scopus 로고    scopus 로고
    • Targeting of HER2- expressing tumors using a site-specifically 99mTc-labeled recombinant Affibody molecule ZHER2:2395 with C-terminal engineered cysteine
    • Ahlgren S, Wallberg H, Tran TA, et al. Targeting of HER2- expressing tumors using a site-specifically 99mTc-labeled recombinant Affibody molecule ZHER2:2395 with C-terminal engineered cysteine. J Nucl Med 2009;50:781
    • (2009) J Nucl Med , vol.50 , pp. 781
    • Ahlgren, S.1    Wallberg, H.2    Tran, T.A.3
  • 24
    • 58149083156 scopus 로고    scopus 로고
    • Effects of lysine-containing mercaptoacetyl-based chelators on the biodistribution of 99mTc-labeled anti-HER2 Affibody molecules
    • Tran T, Ekblad T, Orlova A, et al. Effects of lysine-containing mercaptoacetyl-based chelators on the biodistribution of 99mTc-labeled anti-HER2 Affibody molecules. Bioconjugate Chem 2008;19:2568
    • (2008) Bioconjugate Chem , vol.19 , pp. 2568
    • Tran, T.1    Ekblad, T.2    Orlova, A.3
  • 25
    • 33646261864 scopus 로고    scopus 로고
    • Tumor imaging a using picomolar affinity HER2 binding Affibody molecule
    • Orlova A, Magnusson M, Eriksson T, et al. Tumor imaging a using picomolar affinity HER2 binding Affibody molecule. Cancer Res 2006;66:4339
    • (2006) Cancer Res , vol.66 , pp. 4339
    • Orlova, A.1    Magnusson, M.2    Eriksson, T.3
  • 26
    • 20844462100 scopus 로고    scopus 로고
    • Endocytosis of the somatostatin analogue, octreotide, by the proximal tubule-derived opossum kidney (OK) cell line
    • Barone R, van der Smissen P, Devuyst O, et al. Endocytosis of the somatostatin analogue, octreotide, by the proximal tubule-derived opossum kidney (OK) cell line. Kidney Int 2005;67:969
    • (2005) Kidney Int , vol.67 , pp. 969
    • Barone, R.1    Van Der Smissen, P.2    Devuyst, O.3
  • 27
    • 0142243132 scopus 로고    scopus 로고
    • Transforming growth factor-b1 reduces megalin- and cubilin-mediated endocytosis of albumin in proximal-tubule-derived opossum kidney cells
    • Gekle M, Knaus P, Nielsen R, et al. Transforming growth factor-b1 reduces megalin- and cubilin-mediated endocytosis of albumin in proximal-tubule-derived opossum kidney cells. J Physiol 2003;552:471
    • (2003) J Physiol , vol.552 , pp. 471
    • Gekle, M.1    Knaus, P.2    Nielsen, R.3
  • 28
    • 49049114956 scopus 로고    scopus 로고
    • Comparison of 111In- DOTA-NOC and 111In-DOTA-TATE distribution in the target and dose-limiting tissues: Conflicting results in vitro and in vivo
    • Cihlo J, Melicharová L, Petrik M, et al. Comparison of 111In- DOTA-NOC and 111In-DOTA-TATE distribution in the target and dose-limiting tissues: Conflicting results in vitro and in vivo. Anticancer Res 2008;28:2189
    • (2008) Anticancer Res , vol.28 , pp. 2189
    • Cihlo, J.1    Melicharová, L.2    Petrik, M.3
  • 29
    • 77953872478 scopus 로고    scopus 로고
    • Kit formulation for 99mTc-labeling of recombinant anti-HER2 Affibody molecules with a C-terminally engineered cysteine
    • Ahlgren S, Andersson K, Tolmachev V. Kit formulation for 99mTc-labeling of recombinant anti-HER2 Affibody molecules with a C-terminally engineered cysteine. Nucl Med Biol 2010;37:539
    • (2010) Nucl Med Biol , vol.37 , pp. 539
    • Ahlgren, S.1    Andersson, K.2    Tolmachev, V.3
  • 30
    • 0032857025 scopus 로고    scopus 로고
    • Megalin knockout mice as an animal model of low molecular weight proteinuria
    • Leheste JR, Rolinski B, Vorum H, et al. Megalin knockout mice as an animal model of low molecular weight proteinuria. Am J Pathol 1999;155:136
    • (1999) Am J Pathol , vol.155 , pp. 136
    • Leheste, J.R.1    Rolinski, B.2    Vorum, H.3
  • 31
    • 50249085637 scopus 로고    scopus 로고
    • Slow Internalization Of Anti-HER2 Synthetic Affibody Monomer 111In-DOTA-ZHER2:342-pep2: Implications For Development Of Labeled Tracers
    • Wallberg H, Orlova A. Slow internalization of anti-HER2 synthetic affibody monomer 111In-DOTA-ZHER2:342-pep2: Implications for development of labeled tracers. Cancer Biother Radiopharm 2008;23:435
    • (2008) Cancer Biother Radiopharm , vol.23 , pp. 435
    • Wallberg, H.1    Orlova, A.2
  • 32
    • 0034073250 scopus 로고    scopus 로고
    • Cubilin is an albumin binding protein important for renal tubular albumin reabsorption
    • Birn H, Fyfe JC, Jacobsen C, et al. Cubilin is an albumin binding protein important for renal tubular albumin reabsorption. J Clin Invest 2000;105:1353
    • (2000) J Clin Invest , vol.105 , pp. 1353
    • Birn, H.1    Fyfe, J.C.2    Jacobsen, C.3
  • 33
    • 0030140103 scopus 로고    scopus 로고
    • Reduction of renal uptake of monoclonal antibody fragments by amino acid infusion
    • Behr TM, Becker WS, Sharkey RM, et al. Reduction of renal uptake of monoclonal antibody fragments by amino acid infusion. J Nucl Med 1996;37:829
    • (1996) J Nucl Med , vol.37 , pp. 829
    • Behr, T.M.1    Becker, W.S.2    Sharkey, R.M.3
  • 34
    • 0029738947 scopus 로고    scopus 로고
    • Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo
    • de Jong M, Rolleman EJ, Bernard BF, et al. Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo. J Nucl Med 1996;37:1388
    • (1996) J Nucl Med , vol.37 , pp. 1388
    • De Jong, M.1    Rolleman, E.J.2    Bernard, B.F.3
  • 35
    • 79954991349 scopus 로고    scopus 로고
    • Localization, mechanism and reduction of renal retention of technetium- 99m labeled epidermal growth factor receptor-specific nanobody in mice
    • Gainkam LO, Caveliers V, Devoogdt N, et al. Localization, mechanism and reduction of renal retention of technetium- 99m labeled epidermal growth factor receptor-specific nanobody in mice. Contrast Media Mol Imaging 2011;6:85
    • (2011) Contrast Media Mol Imaging , vol.6 , pp. 85
    • Gainkam, L.O.1    Caveliers, V.2    Devoogdt, N.3
  • 36
    • 57449108683 scopus 로고    scopus 로고
    • Epidermal growth factor receptor signaling in the kidney Key roles in physiology and disease
    • Melenhorst WBWH, Mulder GM, Xi Q, et al. Epidermal growth factor receptor signaling in the kidney. Key roles in physiology and disease. Hypertension 2008;52:987
    • (2008) Hypertension , vol.52 , pp. 987
    • Melenhorst, W.B.W.H.1    Mulder, G.M.2    Xi, Q.3
  • 37
    • 33947193534 scopus 로고    scopus 로고
    • Synthetic Affibody molecules: A novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors
    • Orlova A, Tolmachev V, Pehrson R, et al. Synthetic Affibody molecules: A novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors. Cancer Res 2007;67:2178
    • (2007) Cancer Res , vol.67 , pp. 2178
    • Orlova, A.1    Tolmachev, V.2    Pehrson, R.3
  • 38
    • 79953275504 scopus 로고    scopus 로고
    • Imaging agents for in vivo molecular profiling of disseminated prostate cancer cellular processing of 111in-labeled chx-a¢¢-dtpatrastuzumab and anti-her2 aby-025 affibody molecule by prostate cancer cell lines
    • Malmberg J, Tolmachev V, Orlova A. Imaging agents for in vivo molecular profiling of disseminated prostate cancer. Cellular processing of 111In-labeled CHX-A¢¢-DTPAtrastuzumab and anti-HER2 ABY-025 Affibody molecule by prostate cancer cell lines. Exp Ther Med 2011;2:523
    • (2011) Exp Ther Med , vol.2 , pp. 523
    • Malmberg, J.1    Tolmachev, V.2    Orlova, A.3
  • 39
    • 72149106173 scopus 로고    scopus 로고
    • Design, synthesis and biological evaluation of a multifunctional HER2 specific Affibody molecule for molecular imaging
    • Tran TA, Rosik D, Abrahmse'n L, et al. Design, synthesis and biological evaluation of a multifunctional HER2 specific Affibody molecule for molecular imaging; Eur J Nucl Med Mol Imaging 2009;36:1864
    • (2009) Eur J Nucl Med Mol Imaging , vol.36 , pp. 1864
    • Tran, T.A.1    Rosik, D.2    Abrahmse'n, L.3
  • 40
    • 84862763098 scopus 로고    scopus 로고
    • Order of amino acids in C-terminal cysteine-containing peptide-based chelators influences biodistribution of 99mTc-labeled recombinant Affibody molecules
    • Altai M, Wallberg H, Orlova A, et al. Order of amino acids in C-terminal cysteine-containing peptide-based chelators influences biodistribution of 99mTc-labeled recombinant Affibody molecules. Amino Acids 2012;42:1975
    • (2012) Amino Acids , pp. 42
    • Altai, M.1    Wallberg, H.2    Orlova, A.3
  • 41
    • 33646739287 scopus 로고    scopus 로고
    • Effects of HER2-binding affibody molecules on intracellular signaling pathways
    • Ekerljung L, Steffen AC, Carlsson J, Lennartsson J. Effects of HER2-binding affibody molecules on intracellular signaling pathways. Tumour Biol 2006;27:201
    • (2006) Tumour Biol , vol.27 , pp. 201
    • Ekerljung, L.1    Steffen, A.C.2    Carlsson, J.3    Lennartsson, J.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.